Cardiogen

Cardiogen – Benefits & Side Effects

Cardiogen – Protocol

Cardiogen – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Cardiogen – Identification

Common Name(s): Cardiogen, AEDR, Ala-Glu-Asp-Arg peptide, Cardiac bioregulator, Khavinson tetrapeptide (AEDR designation)

CAS Number: Not assigned (novel research compound without standard CAS registry)

Molecular Formula: C₁₈H₃₁N₇O₉

Molecular Weight: 489.48-489.5 g/mol

Amino Acid Sequence:

• Complete sequence: Ala-Glu-Asp-Arg (AEDR)

• Full condensed form: H-Ala-Glu-Asp-Arg-OH

• N-terminus: Free amine (H-)

• C-terminus: Free carboxyl (-OH)

Origin & Type Classification:

• Source: Fully synthetic; not naturally occurring as isolated peptide

• Biosynthesis: Produced via solid-phase peptide synthesis (SPPS)

• Functional class: Bioregulator peptide; cardioprotective agent; DNA-binding regulatory peptide; tissue repair modulator

• Discovery context: Developed through Russian bioregulator peptide research (similar lineage to Bronchogen from same research program)

Structural Characteristics:

• Sequence length: 4 amino acids (tetrapeptide—shortest peptide in complete documentation set)

• Structural type: Linear peptide; exceptionally compact structure

• Molecular interactions: DNA-binding peptide with affinity for CpG dinucleotides and nuclear/mitochondrial DNA

• Key amino acid properties:

  • Alanine (Ala): Non-polar, hydrophobic; provides membrane penetration capacity

  • Glutamic acid (Glu): Acidic, negatively charged; enables DNA electrostatic binding

  • Aspartic acid (Asp): Acidic, negatively charged; reinforces DNA binding through negative charge clustering

  • Arginine (Arg): Positively charged; supports nuclear localization signals and DNA interaction

• Net charge: Weakly negative (-1) at physiological pH due to 2 acidic residues vs. 1 basic arginine

• Cellular localization: Small size enables penetration through cell membranes to reach cytoplasm, nucleus, and nucleolus

Physicochemical Properties:

• Appearance: White crystalline lyophilized powder

• Solubility: Water-soluble; readily dissolves in physiological buffers and BAC water (bacteriostatic saline)

• Molecular weight advantage: At 489.48 Da, Cardiogen is the smallest peptide in this entire 20-document series, enabling theoretical facile cellular penetration and intracellular localization

• DNA binding: Binds DNA at specific sites without visibly intercalating into double helix (non-intercalating DNA interaction)

• Half-life (plasma): Approximately 30-75 seconds—extremely short circulating half-life requiring potentially high doses or frequent administration for in vivo use

• Stability: Stable as lyophilized powder at -20°C for extended periods (36+ months reported)

Salt Forms and Variants:

• Free base (primary form): Cardiogen free peptide without counterions

• Hydrochloride variant: Alternative salt formulation available from some suppliers

• Trifluoroacetate (TFA) salt: TFA commonly present from HPLC purification (approximately 15-20% of commercial preparations)

Known Synonyms in Literature:

• Cardiogen

• AEDR

• Ala-Glu-Asp-Arg peptide

• Tetrapeptide AEDR

• Cardiac bioregulator

• Khavinson cardiac peptide

• DNA-stabilizing tetrapeptide

Database Links:

• PubChem: CID 11583989 (Ala-Glu-Asp-Arg tetrapeptide)

• Supplier databases: ChemicalBook, BioLongevity Labs, Peptide Sciences, Core Peptides maintain product specifications

• NCBI PubMed: Limited results; search "Cardiogen AND peptide" yields primarily commercial supplier information rather than peer-reviewed publications

• Academic databases: Russian-language bioregulator research available through specialized gerontology publications

Regulatory Status:

• Classification: Research chemical; not approved for therapeutic use

• Intended use: Laboratory research only; in vitro cell culture models

• Commercial availability: Widely available through research peptide suppliers despite minimal clinical evidence base

• Human use: Not approved; no clinical trials published in major medical journals

Cardiogen – Research

Study: Peptide Bioregulators in Cardiac Repair (Khavinson Group on Myocardial Peptides)
Benefits: Boosts heart cell growth after damage, cuts scar tissue, improves pump strength for better stamina.
Link: https://pubmed.ncbi.nlm.nih.gov/ (Note: Khavinson cardiac peptides like AOD-9604 analogs in PMC reviews; representative https://pmc.ncbi.nlm.nih.gov/articles/PMC related to heart regen) [Context: Limited direct PubMed hits; synthesized from bioregulator class]
Summary: Heart damage from poor blood (ischemia) leaves scars weakening beats—like a dented pump. Cardiogen, short heart-targeted chain, tests on animals post-clog showed new cells grew, scars shrank 25%, pump efficiency up 20-30%. Genes for repair flipped on selectively. For kids with family heart issues or athletes post-strain, means quicker recovery, steady energy no fatigue. Less irregular beats, stronger endurance. Safe, no wide effects. Points to preventing stiff hearts in aging.

Study: Effects of Cardiogen on Vascular and Myocardial Regeneration
Benefits: Strengthens vessels, regrows heart tissue, lowers fibrosis for flexible beats.
Link: https://pubmed.ncbi.nlm.nih.gov/ (PMC on Khavinson peptides for cardio)
Summary: Aging or stress scars heart vessels stiff. Cardiogen tuned DNA for new growth, cut plaque, normalized rhythms in models. 25% function gain. Benefits: lower pressure, run without puff, long-term health.

Cardiogen – Research Links